# Surface Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/surface-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.surfacepharma.com
- Total disclosed funding: $41M
- Latest round: Series A (Jul 11, 2018)
- Investors on record: 2

## About

Surface Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing innovative treatments for dry eye syndrome, offering both prescription and over-the-counter solutions that cater to a diverse patient population.Founded in 2017, Surface Pharmaceuticals, Inc. operates from its headquarters in San Diego, US. The company specializes in addressing dry eye syndrome through a focused approach on product development and commercialization. Led by CEO Kamran Hosseini, the firm raised USD 21.00 mn in Series A funding on July 11, 2018, from Visionary Venture Fund, marking its second deal in funding. The company does not have any reported subsidiaries or notable pivots in its operations.Surface Ophthalmics® develops and commercializes treatments for dry eye syndrome (DES), offering a pipeline of prescription and over-the-counter eye drops designed to restore tear film homeostasis. These products are aimed at eyecare professionals (ECPs) and provide solutions for various presentations of dry eye, ensuring a broad reach across North America and select international markets.Surface Ophthalmics® generates revenue primarily through direct sales of its eye drop products to eyecare professionals and retail partnerships. The company engages with ECPs who prescribe or recommend its treatments, which are then available for purchase at pharmacies and specialty eye care outlets. Surface Ophthalmics® may also partner with wholesalers to broaden its market penetration, though specific pricing plans for its products are not disclosed.Looking ahead, Surface Pharmaceuticals, Inc. plans to leverage the USD 21.00 mn raised in its Series A funding to support the development of new products aimed at expanding its portfolio in the dry eye treatment market. The company is also targeting expansion into additional geographic regions, although specific markets and timelines have not been outlined. The recent funding is expected to facilitate these initiatives and bolster the company’s overall growth strategy.

## Funding rounds

- Series A, Jul 11, 2018, $21M — Visionary Venture Fund
- Series A, May 15, 2018, $20M — Flying L Partners

## Investors

- Flying L Partners (https://capitalatlas.ai/funds/flying-l-partners) — Series A
- Visionary Venture Fund (https://capitalatlas.ai/funds/visionary-venture-fund) — Series A